About Anthem Biosciences
Anthem Biosciences is a company based in Bengaluru (India) founded in 2007 by Ravindra K C, Ganesh Sambashivam, and Ajay Bharadwaj. Anthem Biosciences has raised $35.74 million across 4 funding rounds from investors including Department of Biotechnology, True North and Portsmouth Technologies Trials Unit. The company has 1,820 employees as of March 31, 2023. Anthem Biosciences offers products and services including Chemistry Services, Biology Services, and Biologics Services. Anthem Biosciences operates in a competitive market with competitors including Abzena, Patheon, Syngene, Piramal Group and Panacea Biotec, among others.
- Headquarter Bengaluru, India
- Employees 1820 as on 31 Mar, 2023
- Founders Ravindra K C, Ganesh Sambashivam, Ajay Bharadwaj
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Anthem Biosciences Limited
-
Annual Revenue
$170.19 M (USD)34.29as on Mar 31, 2024
-
Net Profit
$44.02 M (USD)-4.64as on Mar 31, 2024
-
EBITDA
$61.77 M (USD)18.3as on Mar 31, 2024
-
Total Equity Funding
$35.74 M (USD)
in 4 rounds
-
Latest Funding Round
$33.41 M (USD), Series A
Mar 01, 2021
-
Investors
Department of Biotechnology
& 3 more
-
Employee Count
1820
as on Mar 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Anthem Biosciences
Anthem Biosciences is a publicly listed company on the NSE with ticker symbol ANTHEM in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Anthem Biosciences
Anthem Biosciences offers a comprehensive portfolio of products and services, including Chemistry Services, Biology Services, and Biologics Services.
Provides chemical discovery and development for life sciences applications.
Offers gene design and biologics manufacturing for health innovations.
Delivers biologics production with quality and compliance focus.
People of Anthem Biosciences
Unlock access to complete
Unlock access to complete
Funding Insights of Anthem Biosciences
Anthem Biosciences has successfully raised a total of $35.74M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $33.41 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Anthem Biosciences
Anthem Biosciences has secured backing from 4 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Department of Biotechnology, True North and Portsmouth Technologies Trials Unit.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity is invested by True North in mid-market companies.
|
Locked | Locked | Locked | |
|
Research in healthcare technologies is supported by this unit.
|
Locked | Locked | Locked | |
|
Biotechnology research, guidelines, and funding by the Government of India.
|
Locked | Locked | Locked |
Investor details for Anthem Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Anthem Biosciences
Investment portfolio details for Anthem Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Anthem Biosciences
Detailed financials for Anthem Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Anthem Biosciences Comparisons
Peer comparison for Anthem Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Anthem Biosciences
Anthem Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abzena, Patheon, Syngene, Piramal Group and Panacea Biotec, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of antibody discovery, cell line development, and bio analytics services
|
|
| Locked | Locked | Locked |
Commercial manufacturing and pharmaceutical development services for biopharmaceutical industry
|
|
| Locked | Locked | Locked |
Provider of contract research and manufacturing services for both small molecules and biologics
|
|
| Locked | Locked | Locked |
Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate
|
|
| Locked | Locked | Locked |
Developer of biosimilars, vaccines and natural products
|
|
| Locked | Locked | Locked |
Provides enabling tools and services in the life sciences research and bio-production industries
|
Detailed competitors of Anthem Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Anthem Biosciences
Complete news archive for Anthem Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anthem Biosciences
Anthem Biosciences was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Anthem Biosciences is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Ajay Bharadwaj is the current CEO of Anthem Biosciences. They have also founded this company.
Anthem Biosciences is a funded company, having raised a total of $35.74M across 4 funding rounds to date.
As of Mar 31, 2023, the latest employee count at Anthem Biosciences is 1,820.
Annual revenue of Anthem Biosciences is $170.19M as on Mar 31, 2024.
Developer of integrated contract research development and manufacturing services. The company offers endtoend drug discovery, development and manufacturing support for small molecules, biologics and nutritional actives. It provides medicinal chemistry, process synthesis, analytical RD, toxicology and GLP preclinical testing under one roof. Services include microbial screening, protein expression, peptide synthesis, antibody drug conjugates and fermentation scaleup capable from milligram to tonne volumes. The infrastructure includes cGMP kilolabs, pilot manufacturing and AAALAC accredited vivarium for in vitro and in vivo studies. Quality control, regulatory compliance and analytical method development are embedded as part of the scientific service portfolio.
Anthem Biosciences's top competitors include Abzena, Syngene and Grand River Aseptic Manufacturing.
Anthem Biosciences offers Chemistry Services, Biology Services, and Biologics Services.
Yes, Anthem Biosciences is publicly traded on NSE under the ticker symbol ANTHEM.
Anthem Biosciences has 4 investors. Key investors include Department of Biotechnology, True North, Portsmouth Technologies Trials Unit, and Muppala Raju.
The ticker symbol of Anthem Biosciences is ANTHEM on NSE.
The valuation of Anthem Biosciences is $999.08M as of Mar 2021.